National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Brentuximab vedotin (Adcetris®) for CD30+ Hodgkins lymphoma HTA ID: 19058

Brentuximab vedotin (Adcetris®) is indicated for the treatment of adult patients with CD30+ Hodgkin’s lymphoma at increased risk of relapse or progression following autologous stem cell transplant.

 

NCPE Assessment Process Complete
Rapid review commissioned 30/12/2019
Rapid review completed 29/01/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of brentuximab vedotin compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 05/02/2020
Pre-submission consultation with Applicant 19/05/2020
Full submission received from Applicant 11/01/2021
Preliminary review sent to applicant 12/07/2021
NCPE assessment re-commenced 06/08/2021
Factual accuracy check sent to Applicant 24/09/2021
NCPE assessment re-commenced 30/09/2021
NCPE assessment completed 22/10/2021
NCPE assessment outcome The NCPE recommends that brentuximab vedotin be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments.*

Technical Summary

Plain English Summary

* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medicinal Goods) Act 2013.